CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference65 articles.
1. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3);Cardoso;Ann Oncol,2017
2. Mechanisms of endocrine resistance in breast cancer;Osborne;Annu Rev Med,2011
3. Hallmarks of cancer: the next generation;Hanahan;Cell,2011
4. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers;Finn;Breast Cancer Res,2016
5. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat Rev Drug Discov,2015
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors;Redox Biology;2024-10
2. Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer;Current Oncology;2024-09-12
3. Management of Diffuse Carcinomatosis of the Bone Marrow from Occult Breast Cancer with Abemaciclib and Letrozole: Case Report and Literature Review;Indian Journal of Medical and Paediatric Oncology;2024-07-18
4. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer;Clinical Cancer Research;2023-11-28
5. Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer;npj Breast Cancer;2023-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3